Last reviewed · How we verify

NCT07040332

Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis

Recruiting now Last updated 4 July 2025
What this trial tests

trial in Allergic Bronchopulmonary Aspergillosis (ABPA) in 140 participants. Currently enrolling.

Timeline
10 May 2025
Primary endpoint
31 July 2027
31 January 2029

Quick facts

Lead sponsorQianfoshan Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment140
Start date10 May 2025
Primary completion31 July 2027
Estimated completion31 January 2029
Sites1 location across China

Conditions studied

Sponsor

Qianfoshan Hospital

Who can join

18 and older, any sex, with Allergic Bronchopulmonary Aspergillosis (ABPA). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Allergic Bronchopulmonary Aspergillosis (ABPA)

Currently open trials in the same condition.

Other Qianfoshan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07040332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing